ESR1 and breast carcinoma: Our previous studies have shown that singular treatment with EGCG or SFN inhibits breast cancer initiation by epigenetically mediating many tumor-related gene expressions such as hTERT and estrogen receptor-α (ERα)5, 6, 18.